• In August 2026, Cardinal Health reported higher fourth-quarter and full-year results, including US$63,672 million in quarterly sales and US$398 million in quarterly net income, while also expanding its revolving credit capacity to US$4.00 billion and authorizing a new US$5.00 billion share repurchase program.
• Together with a regular quarterly dividend declaration of US$0.5158 per share and continued product recall activity, these moves highlight Cardinal Health’s focus on returning capital to shareholders while managing operational and quality-control risks.
• Next, we’ll examine how the expanded US$5.00 billion buyback plan may reshape Cardinal Health’s existing investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Cardinal Health Investment Narrative Recap

To own Cardinal Health today, you need to believe its scale in drug and medical distribution, plus growth in higher-margin services, can offset thin margins and regulatory or quality setbacks. The latest earnings beat and expanded US$5.00 billion buyback appear supportive of the near term earnings per share growth story, while the ongoing drug recalls keep operational and quality risk squarely in view and may be the most important risk to watch near term.

Among the recent announcements, the new US$4.00 billion revolving credit facility stands out because it refreshes Cardinal Health’s liquidity and replaces multiple older lines. For investors focused on buybacks and ongoing investment in specialty and at home businesses, this facility underpins financial flexibility without, on its own, changing the core thesis or addressing the underlying exposure to product recalls and regulatory scrutiny.

Yet even with higher earnings and a larger buyback, investors should be aware of how recurring product recalls could...

Cardinal Health's narrative projects $302.9 billion revenue and $2.4 billion earnings by 2029. This requires 6.0% yearly revenue growth and about a $0.7 billion earnings increase from $1.7 billion today.

Uncover how Cardinal Health's forecasts yield a $264.73 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$264.73 to US$741.92 per share, underscoring how far apart individual views can be. When you set those against Cardinal Health’s thin margins and exposure to ongoing product recall and regulatory risks, it becomes even more important to compare several different opinions before deciding how this business might fit in your portfolio.

Explore 3 other fair value estimates on Cardinal Health - why the stock might be worth just $264.73!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.